An update from Moleculin Biotech (MBRX) is now available.
Moleculin Biotech, Inc. is moving forward with a Phase 3 pivotal trial for Annamycin, in combination with Cytarabine, to treat Acute Myeloid Leukemia (AML) patients who haven’t responded to initial therapy. The company shared this significant development during a corporate update webcast, emphasizing their commitment to addressing the needs of R/R AML patients. Details from the presentation can be found on Moleculin’s website, showcasing their ongoing efforts to innovate in the field of cancer treatment.
See more insights into MBRX stock on TipRanks’ Stock Analysis page.
